GF Fund Management’s Arcturus Therapeutics ARCT Stock Holding History

GF Fund Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.11K	Sell	611 -42	-6%	-$331	﹤0.01%	577
2026 Q1	$5.04K	Buy	653 +76	+13%	+$555	﹤0.01%	606
2025 Q4	$3.54K	Sell	577 -8	-1%	-$86	﹤0.01%	633
2025 Q3	$10.8K	Sell	585 -108	-16%	-$1.74K	﹤0.01%	549
2025 Q2	$9.02K	Hold	693	–	–	﹤0.01%	580
2025 Q1	$7.34K	Buy	693 +124	+22%	+$1.97K	﹤0.01%	597
2024 Q4	$9.66K	Buy	+569	New	+$10.7K	﹤0.01%	550

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

GF Fund Management's ARCT Position: Q2 2026 in Review

GF Fund Management reduced its Arcturus Therapeutics (ARCT) stake by 6.4% in Q2 2026, selling an estimated $331 and leaving 611 shares worth $4.11K. The position accounts for ﹤0.01% of the portfolio, ranked #577.

GF Fund Management first reported a position in ARCT in Q4 2024 and has held it in 7 quarters since. The position peaked at $10.8K in Q3 2025. 136 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

GF Fund Management held 611 shares of Arcturus Therapeutics worth $4.11K as of Q2 2026.
GF Fund Management sold 42 Arcturus Therapeutics shares in Q2 2026, an estimated $331.
Arcturus Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #577 holding.
GF Fund Management first reported a position in Arcturus Therapeutics in Q4 2024 and has held it in 7 quarters since.
GF Fund Management's Arcturus Therapeutics position peaked at $10.8K in Q3 2025.
136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.